Edition:
United States

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.42USD
2:46pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.42
Open
$1.44
Day's High
$1.44
Day's Low
$1.39
Volume
105,404
Avg. Vol
217,624
52-wk High
$3.00
52-wk Low
$1.35

Chart for

About

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in... (more)

Overall

Beta: -0.53
Market Cap(Mil.): $97.20
Shares Outstanding(Mil.): 67.97
Dividend: --
Yield (%): --

Financials

  TRVN.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -0.99 -- --
ROI: -82.82 -3.67 13.17
ROE: -116.14 -5.61 15.10

BRIEF-Trevena Appoints Mark Demitrack As Chief Medical Officer

* TREVENA APPOINTS MARK A. DEMITRACK, M.D., AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

May 21 2018

BRIEF-Trevena Q1 Loss Per Share $0.14

* Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S

May 03 2018

BRIEF-Trevena Inc And Jiangsu Nhwa Pharmaceutical Announce License Agreement For Oliceridine In China

* TREVENA INC. AND JIANGSU NHWA PHARMACEUTICAL CO. LTD ANNOUNCE LICENSE AGREEMENT FOR OLICERIDINE IN CHINA

May 01 2018

BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018

* TREVENA SAYS ON APRIL 9, ROBERTO CUCA, CHIEF FINANCIAL OFFICER OF CO FORMALLY NOTIFIED CO OF HIS RESIGNATION, EFFECTIVE AS OF MAY 3, 2018 - SEC FILING Source text: (https://bit.ly/2GVszsP) Further company coverage:

Apr 12 2018

BRIEF-Trevena Reports Q4 Loss Per Share $0.24

* COMPANY EXPECTS THAT EXPENSES WILL DECREASE IN 2018 COMPARED TO 2017

Mar 07 2018

Earnings vs. Estimates